particularly in patients requiring indwelling medical devices, such as catheters and prostheses. 73 They have recently been associated with about 80% of all chronic human infections (3) and 74 described as important mediators of healthcare-associated infections (4). 75 Osteomyelitis, infective endocarditis, chronic wounds, and infections related to The strains used in this study are listed in Table 1 . They were maintained as follows:
152
Pseudomonas aeruginosa was grown in Lysogeny Broth (LB) medium, Escherichia coli was 
Antimicrobial activities against planktonic cultures

158
To investigate the antimicrobial activities of dermaseptins ( Table 1 
Statistical analysis
239
Normality in this study was assessed using Proc Univariate in SAS software (37). All data 240 were statistically analyzed using the least-squares method with the procedure GLM for
241
General Linear Model. Effects were treatment, bacteria and the interaction treatment-bacteria.
242
The SNK multivariate test was used to compare means for bacteria and Dunnett's test to 
RESULTS
255
In vitro toxicity of dermaseptin and derivatives against human cells 256 We tested the potential in vitro cytotoxicity of dermaseptin S 4 and its derivatives 257 (described in Table 2 ) in confluent monolayers of human HeLa cells using the MTT cell 258 viability assay. Cells were exposed to increasing concentrations of peptides ranging from 0 to 259 128 µg/ml. Cytotoxicity of dermaseptins was concentration-dependent (data not shown).
260
Peptides concentrations that caused 50% cytotoxixity (CC 50 ) were determined ( (Fig 2A and B) showed that, suggesting that this peptide has the ability to inhibit biofilm proliferation (Fig 2A) . This was
305
verified by quantitative analysis of bacterial biomass that showed that biofilm proliferation 306 was stopped right after injection of K 4 S 4 (Fig. 3) . Co-localization measurements indicated that it was not as effective as K 4 S 4 (co-location measures), and appeared to be unable to stop the 314 growth of E. coli biofilm (Fig 3) .
315
Among all peptides tested, we found that K 4 K 20 S 4 and K 4 S 4 were the most potent to 316 inhibit biofilm formation with non toxic concentrations comparing to the others peptides. We 317 also showed that this inhibition of growth was dependent on the nature of the peptide, and the 318 highly charged molecules were the most active. work has a number of advantages over other antibiofilm cationic peptides tested. active against all the tested biofilm even at low concentrations, suggesting that the matrix may 418 not hold these peptides which are positively charged and that they can reach the target cells. To allow attachment of the bacterial cell to the substratum, flow cells were left without flow for 1h after inoculation at 37°C. Afterwards, a laminar flow with a flowrate of 2µl/sec was activated. After 5h of biofilm growth, the flow was stopped and 300 µl (0.78 µg/ml for K 4 S 4 and 25 µg/ml for D 4 D 20 S 4 ) of each peptide sample was added. Confocal images acquisition showed that the fluorescent peptide (A): K 4 S 4 (green) has an instant effect on biofilm and stops its formation under dynamic flow conditions. Whereas, D 4 D 20 S 4, at 25µg/ml, (B), shows a less activity, biofilm cells exhibit high fluorescent signals (red) and survived the dermaseptin treatment. Figure 3 . Confocal assays were confirmed by the quantification of biofilms. Differences in bacterial survival in the biofilms were quantified using the computer program Imaris MeasurementPro. Statistical analysis was performed by using SNK multivariate test and Dunnett's test. K 4 S 4 was significantly different from control (p<0.001).
